Hien Le

Royal Adelaide Hospital

Papers

2

Total Citations

495

H-Index

2

About

Dr. Hien Le is a leading clinical researcher in head and neck oncology, whose work has fundamentally shaped the debate on treatment de-escalation for oropharyngeal squamous cell carcinoma (OPSCC). Her primary research focus lies in comparing the efficacy and quality-of-life outcomes of radiotherapy versus transoral robotic surgery (TORS) for this disease. Dr. Le is best known as the lead author of the landmark ORATOR trial, a phase 2 randomized study published in 2019 that directly compared these two curative-intent modalities. This pivotal work, which has garnered over 458 citations, provided critical early evidence on swallowing function and survival, challenging existing treatment paradigms. She subsequently led the final 5-year outcomes of the ORATOR trial in 2024, solidifying the study’s long-term impact. Through this rigorous, practice-informing research, Dr. Le has provided oncologists and patients with essential data to navigate complex treatment decisions, establishing herself as a key voice in the ongoing effort to optimize both oncologic control and functional preservation in head and neck cancer care.

Research Focus

Key Achievements

2
H-Index
2
Papers
495
Total Citations
248
Avg Citations/Paper
🏆 Most Cited Paper
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial
458 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 35
🏛 Institutions: Royal Adelaide Hospital

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago